S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69

Unity Biotechnology Stock Forecast, Price & News

-0.13 (-5.88%)
(As of 11/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
852,905 shs
Average Volume
636,173 shs
Market Capitalization
$120.07 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology logo

About Unity Biotechnology

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in Brisbane, CA.


Unity Biotechnology (NASDAQ:UBX) Issues Earnings Results
November 11, 2021 |  americanbankingnews.com
Unity Biotechnology (NASDAQ:UBX) Upgraded to "Buy" by Mizuho
November 9, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$120.07 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.73 out of 5 stars

Medical Sector

893rd out of 1,392 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

Is Unity Biotechnology a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Unity Biotechnology stock.
View analyst ratings for Unity Biotechnology
or view top-rated stocks.

How has Unity Biotechnology's stock price been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, UBX shares have decreased by 61.4% and is now trading at $2.08.
View which stocks have been most impacted by COVID-19

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a drop in short interest in the month of October. As of October 15th, there was short interest totaling 1,180,000 shares, a drop of 33.3% from the September 30th total of 1,770,000 shares. Based on an average daily trading volume, of 388,400 shares, the days-to-cover ratio is presently 3.0 days. Currently, 3.4% of the shares of the company are sold short.
View Unity Biotechnology's Short Interest

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Unity Biotechnology

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06.
View Unity Biotechnology's earnings history

What price target have analysts set for UBX?

3 brokerages have issued twelve-month price targets for Unity Biotechnology's stock. Their forecasts range from $6.00 to $12.00. On average, they expect Unity Biotechnology's share price to reach $8.33 in the next year. This suggests a possible upside of 300.6% from the stock's current price.
View analysts' price targets for Unity Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Anirvan Ghosh, Chief Executive Officer & Director
  • Nathan Guz, Vice President-Operations
  • Lynne Sullivan, Chief Financial Officer
  • Jamie Dananberg, Chief Medical Officer
  • Susan Lundeen Smuck, Chief Human Resources Officer

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.63%), Renaissance Technologies LLC (1.16%), Baillie Gifford & Co. (1.07%), Morgan Stanley (0.91%), GSA Capital Partners LLP (0.85%) and Millennium Management LLC (0.80%).
View institutional ownership trends for Unity Biotechnology

Which institutional investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Morgan Stanley, Millennium Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and Citadel Advisors LLC.
View insider buying and selling activity for Unity Biotechnology
or view top insider-selling stocks.

Which institutional investors are buying Unity Biotechnology stock?

UBX stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Renaissance Technologies LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Franklin Resources Inc., Marshall Wace LLP, Moloney Securities Asset Management LLC, and BlackRock Inc..
View insider buying and selling activity for Unity Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $2.08.

How much money does Unity Biotechnology make?

Unity Biotechnology has a market capitalization of $120.07 million.

How many employees does Unity Biotechnology have?

Unity Biotechnology employs 61 workers across the globe.

What is Unity Biotechnology's official website?

The official website for Unity Biotechnology is www.unitybiotechnology.com.

How can I contact Unity Biotechnology?

The company can be reached via phone at (650) 416-1192.

This page was last updated on 11/30/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.